Edwards Lifesciences (EW) Financial Report Summaries

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adaptive, aforementioned, agent, al, Alterra, approach, assembled, BD, behalf, bench, caption, captioned, Central, Codification, complaint, conclusion, disbursed, enforcement, equipment, false, focused, framework, indefinite, indemnification, influence, introduction, invasive, JC, lease, letter, merger, misleading, ongoing, ownership, paper, Patel, prestent, pulmonary, purported, putative, realignment, recommending, remeasured, remeasurement, revision, scheduled, serving, small, stable, step, stockholder, testing, therapeutic, Topic, undisclosed, unfavorable, unmet

Removed: announced, counsel, determination, ENCIRCLE, equitable, Euro, execution, imposition, negative

From filing 10-Q 2024 Q3

Financial report summary

Competition

Abbott Laboratories • Baxter International • Medtronic • Canada • Artivion • Abiomed • Merit Medical Systems • ICU Medical • Boston Scientific • Masimo

Management Discussion

Net sales outside of the United States include the impact of foreign currency exchange rate fluctuations. The impact of foreign currency exchange rate fluctuations on net sales is not necessarily indicative of the impact on net income due to the corresponding effect of foreign currency exchange rate fluctuations on international manufacturing and operating costs, and our hedging activities.
•foreign currency exchange rate fluctuations, which decreased net sales outside of the United States by $5.9 million and $18.4 million for the three and nine months ended September 30, 2024, respectively, primarily due to the weakening of the Japanese yen against the United States dollar.
While our global competitive position and pricing remained stable during the first nine months of 2024, we experienced some regional sales pressure and a reduction in procedures with certain hospital centers in the United States related to a variety of factors including, but not limited to, resources and priorities.